Genetic Analysis AS (8V8)

Overview

Genetic Analysis AS operates within the forefront of the science-driven diagnostic arena, primarily focused on the burgeoning human microbiome market. Founded in 2008 and based in Oslo, Norway, the company has carved a niche for itself by developing innovative diagnostic solutions that cater to a wide range of health issues related to gut microbiota. Their approach combines state-of-the-art molecular assays with sophisticated data analysis techniques to offer breakthrough diagnostics that target conditions such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), diabetes type 2, and other lifestyle diseases. Furthermore, in response to the global COVID-19 pandemic, Genetic Analysis AS expanded its product line to include diagnostic solutions for detecting the novel coronavirus in fecal samples, showcasing the company's adaptability and commitment to addressing emergent health crises.

Products and Services

• GA-map Dysbiosis Test Lx

  A state-of-the-art molecular assay designed for profiling the gut microbiota. This tool is essential for identifying and characterizing dysbiosis, a microbial imbalance linked to various conditions including Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), diabetes type 2, amongst others. The GA-map Dysbiosis Test Lx aims to facilitate targeted treatment approaches by providing detailed insights into the microbiome's condition.

• GA-map COVID-19 Fecal Test Kit

  This kit represents a significant leap in COVID-19 diagnostics by offering a qualitative, real-time standardized PCR test for the detection of the novel coronavirus RNA in stool samples. The move to include fecal testing options broadens the scope of COVID-19 diagnostics, aiding in the comprehensive tracking and understanding of the virus's spread, including possible fecal-oral transmission routes.

• GA-map Dysbiosis Test Reagent Kit

  Carrying the CE-IVD documentation, this reagent kit is part and parcel of the GA-map Dysbiosis Test Lx ecosystem. It includes software that performs quality control on the run file, calculates the dysbiosis index score and abundance table, and converts sample results into detailed reports. This reagent kit streamlines the process of dysbiosis index determination, thereby facilitating a more straightforward diagnosis of gut microbiota imbalances.

• GA-map Covid Fecal Test Reagent Kit

  Also a CE-IVD documented test, this reagent kit complements the GA-map COVID-19 Fecal Test Kit by providing all necessary components to detect SARS-CoV-2 in fecal samples. This kit underscores Genetic Analysis AS's effort in expanding diagnostic capabilities to encompass novel and emergent pathogens by leveraging advanced testing methodologies.